Navigation Links
/C O R R E C T I O N -- Rosetta Genomics Ltd/
Date:11/6/2008

nd its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Media & Investors

Ron Kamienchick

T: +972-73-222-0730

E: media@rosettagenomics.com

------

Rosetta Genomics to Present at Rodman & Renshaw 10th Annual Healthcare Conference

REHOVOT, Israel and JERSEY CITY, New Jersey, November 5 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based dia
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 02, 2014 Myriant Corporation, a ... of a distribution agreement with Azelis Group, a ... Myriant’s bio-succinic acid in the Nordics, Benelux, France, ... customers in the industrial and base chemicals markets. ... offers a far-reaching chemical portfolio with extensive distribution ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 The inventors ... cure for chronic tinnitus are seeking support for development ... the Indiegogo platform ( http://igg.me/at/tinaway ), was launched on ... a therapeutic ‘mHealth’ app and is based on ten ... a team of biomedical and software engineers, Dr. Ian ...
(Date:8/31/2014)... Available spectra is similar for ... and cultivation of a wide range of plants. ... with proven patented and pending wide spectrum technology. ... in critical applications in contrast to growth spectra ... customers have a large variety of differently sized ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... expansion of PROVENT(R) Sleep Apnea Therapy in Limited ... Inc. a privately-held, medical device company, focused on ... the appointment of John McCutcheon as President and ... company also announced that current CEO Jeffrey Nugent ...
... Group (OTC Bulletin Board: SNBP) is pleased to ... Director of Marketing.Ms. Tan joins Sinobiopharma from Organon ... China-based Unit Marketing Director for Organon, which was ... Tan held senior marketing management roles at China ...
... Kiadis,Pharma reported preliminary clinical data on ATIR(TM) ... Data was presented by the,company,s principal investigator ... Symposium at the Annual European Bone Marrow ... March 30, 2009. Only the 6,highest ranked ...
Cached Biology Technology:Ventus Medical Appoints John McCutcheon as President and CEO 2Sinobiopharma, Inc. Appoints New Director of Marketing 2Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations 2
(Date:9/2/2014)... through a U.S. suburb , Observations and mapping ... the hours and days after the August 24 earthquake ... earthquake caused so much damage in the region, according ... by the American Geophysical Union. , ... Places to Direct Our Curiosity , Selecting where ...
(Date:9/2/2014)... The Field Museum will present the prestigious Parker/Gentry Award ... commitment to biodiversity conservation awareness. The Parker/Gentry Award is ... individual, team or organization whose efforts have had a ... and whose actions can serve as a model to ... an environmental science and conservation news website that draws ...
(Date:9/2/2014)... In Bavaria, the Tithonian Konservat-Lagersttte of lithographic limestone ... discoveries of emblematic fossils from that area (for ... have found fossil insects in the French equivalent ... new species representing the oldest known water treader. ... equivalent Bavarian outcrops, fewer fossils have been obtained ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... marine animals find their way back to their birthplace to ... has mystified scientists for more than a century. But marine ... think they might finally have unraveled the secret. At ... read the magnetic field of their home area and "imprint" ...
... from the California Institute of Technology (Caltech) have created ... the first time, the connection between the configuration of ... More precisely, they showed that the muscular band--which ... a helix--is actually a sort of twisting highway along ...
... (ST. LOUIS): The Missouri Botanical Garden Press (MBG ... species of vascular plants for the Southern Cone region, ... Plantas Vasculares del Cono Sur (Catalogue of the Plants ... the plants of Argentina, southern Brazil, Chile, Paraguay and ...
Cached Biology News:No place like home: New theory for how salmon, sea turtles find their birthplace 2No place like home: New theory for how salmon, sea turtles find their birthplace 3Caltech scientists show function of helical band in heart 2Missouri Botanical Garden publishes first catalogue of plants of the Southern Cone 2
... label transfer is fast emerging as a ... and confirmation. Until now, only amino groups ... label transfer reagents such as our Sulfo-SBED. ... Mts-Atf-LC-Biotin, are exciting additions to the protein ...
... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
... transfer is fast emerging as a powerful ... confirmation. Until now, only amino groups have ... transfer reagents such as our Sulfo-SBED. Sulfhydryl-reactive ... are exciting additions to the protein interaction ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
Biology Products: